Nursing Guide to Gout: Nursing Diagnosis, Interventions, & Care Plans

Gout is an inflammatory arthritis triggered by the deposition of monosodium urate (MSU) crystals in joints and other tissues. It develops in the setting of sustained hyperuricemia, usually defined as a serum urate level above the physiologic saturation point for urate (approximately 6.8 mg/dL at physiologic temperature and pH).  

When urate concentrations remain elevated over time, crystals can form and deposit in and around joints, tendons, bursae, cartilage, and soft tissues. The immune system recognizes these crystals as danger signals, triggering acute, often severe inflammation.  

Clinically, gout is characterized by episodic “flares” of abrupt onset joint pain, swelling, warmth, and erythema. Over time, without effective urate-lowering management, gout can progress to chronic arthritis, joint damage, and tophaceous deposits (tophi) that may impair function and quality of life. 

Although gout is sometimes portrayed as a simple diet-related condition, it is more accurately understood as a complex metabolic and inflammatory disease. Most hyperuricemia in gout reflects reduced renal excretion of urate, influenced by genetics, kidney function, and medications.  

Dietary factors, alcohol use, obesity, and comorbid conditions also play meaningful roles, but diet alone rarely explains persistent hyperuricemia. Nursing care, therefore, benefits from a balanced approach that addresses lifestyle factors without blaming the patient, while emphasizing the medical nature of gout and the effectiveness of evidence-based therapies. 

Pathophysiology in practical nursing terms 

Urate is the final breakdown product of purine metabolism in humans. Unlike many mammals, humans don’t have the enzyme uricase, which converts urate into a more soluble compound. As a result, urate levels are relatively high and can reach saturation. When MSU crystals deposit, they can remain clinically silent for long periods. Acute gout flares occur when crystals in the joint space trigger an innate immune response.  

Macrophages and other immune cells activate inflammatory pathways (including the NLRP3 inflammasome), leading to increased interleukin-1 (IL-1) and recruitment of neutrophils. This explains the rapid onset, intensity of pain, and dramatic swelling typical of gout flares. 

The natural history often follows this pattern: 

1. Asymptomatic hyperuricemia: Serum urate is elevated, but there are no symptoms.
2. Acute gout flare: Sudden inflammatory arthritis, often monoarticular.
3. Intercritical gout: Symptom-free periods between flares.
4. Chronic gout: Frequent flares, chronic synovitis, erosive joint disease, and possible tophi. 

The course of the condition is variable. Some people experience a single flare and long remission, while others develop frequent attacks and chronic disease. Clinical progression is more likely when serum urate remains elevated, when urate-lowering therapy isn’t used or is underdosed, and when comorbid risk factors aren’t addressed. 

Clinical significance and nursing impact 

Gout is common and strongly associated with other cardiometabolic and renal conditions, including hypertension, chronic kidney disease (CKD), obesity, diabetes, metabolic syndrome, and cardiovascular disease. Many patients take medications that influence urate handling, such as thiazide or loop diuretics. These comorbidities shape both gout risk and the safety profile of common gout treatments. 

For nurses, gout is important for several reasons: 

• Pain and functional limitation can be severe. Acute flares can cause sudden immobility, sleep disruption, and inability to perform activities of daily living.
• Gout can mimic serious conditions. Septic arthritis can present similarly and may coexist in high-risk patients. Accurate triage and escalation are essential.
• Treatments require careful monitoring. NSAIDs, colchicine, and corticosteroids have important contraindications and adverse effects, especially in older adults and those with renal, gastrointestinal, or cardiovascular disease.
• Long-term success depends on education and adherence. Urate-lowering therapy (ULT) is preventive, not primarily analgesic. Patients often stop medication when they feel better, which leads to relapse.
• Stigma and misconceptions are common. Patients may feel blamed for “lifestyle choices.” A respectful, evidence-based approach improves engagement and outcomes. 

Nursing practice supports gout care across settings: emergency and urgent care (acute flares and exclusion of infection), inpatient units (pain control, mobility, medication safety), primary care and specialty clinics (education, monitoring ULT, comorbidity coordination), and perioperative or rehabilitation settings (mobility plans and fall prevention). 

Etiology and epidemiology 

Urate metabolism and causes of hyperuricemia 

Hyperuricemia results from one or both of the following: 

• Underexcretion of urate (most common): Kidneys excrete a large proportion of the daily urate load. Reduced glomerular filtration, tubular handling changes, and medication effects can decrease urate excretion.
• Overproduction of urate (less common): Increased purine turnover or intake leads to higher urate production. This may occur with high cell turnover states or rare enzyme disorders. 

In clinical practice, most people with gout have impaired renal urate excretion, often influenced by genetics and kidney function. Importantly, hyperuricemia alone does not confirm gout, and not all people with hyperuricemia develop gout. However, sustained hyperuricemia is a prerequisite for MSU crystal deposition. 

Risk factors and triggers 

Nonmodifiable and demographic factors 

• Male sex (risk increases in men earlier in adulthood)
• Postmenopausal status in women (risk rises after menopause)
• Family history and genetic variants influencing urate transport
• Increasing age 

Comorbid conditions 

• CKD and reduced glomerular filtration rate
• Hypertension
• Obesity and metabolic syndrome
• Diabetes and insulin resistance
• Cardiovascular disease and heart failure
• Obstructive sleep apnea (associated with intermittent hypoxia and metabolic stress) 

Medications that can increase serum urate 

• Thiazide and loop diuretics (commonly implicated)
• Low-dose aspirin (high-dose aspirin can lower urate, but is rarely used for this purpose)
• Calcineurin inhibitors (cyclosporine, tacrolimus)
• Some chemotherapy agents due to tumor lysis and increased purine breakdown 

Dietary and lifestyle factors 

• High intake of purine-rich foods (organ meats, some seafood such as anchovies, sardines, shellfish)
• High-fructose corn syrup and sugar-sweetened beverages (fructose metabolism increases urate production)
• Alcohol, particularly beer and spirits (beer contains purines and alcohol reduces urate excretion)
• Dehydration (concentrates urate and may precipitate flares)
• Rapid weight loss or fasting (can increase urate and trigger flares) 

Common flare triggers 

• Dietary excess and alcohol, especially around holidays
• Trauma or surgery
• Acute medical illness, including infection
• Dehydration
• Initiation, interruption, or dose changes of ULT (crystal mobilization can precipitate flares early in therapy)
• Diuretic intensification 

Nurses can help patients identify individual triggers while emphasizing that flares are driven by crystal and immune processes, not simply a single meal. 

Epidemiology 

Gout is among the most common inflammatory arthritides. Prevalence varies by region, age, sex, and comorbidity burden. Population data from national surveys and cohort studies have shown that gout prevalence has increased over recent decades, likely reflecting aging populations, rising obesity and metabolic disease, and medication patterns (for example, diuretic use).  

In the U.S., analyses of National Health and Nutrition Examination Survey (NHANES) data have estimated higher rates in older adults and men. Exact current figures can shift over time due to changing demographics and diagnostic patterns. (For background prevalence and trends, see NHANES-based analyses such as Zhu et al., 2011, and related epidemiologic literature.¹) 

Complications 

Musculoskeletal 

• Recurrent flares with progressive joint involvement
• Chronic synovitis and erosive changes
• Tophi in joints, bursae, tendons, and soft tissues, which can ulcerate or become infected
• Reduced mobility and functional impairment, increased fall risk during acute flares 

Renal 

• Uric acid nephrolithiasis (kidney stones)
• Uric acid nephropathy is uncommon but can occur in high urate turnover states
• CKD may worsen urate handling and complicate medication selection 

Cardiometabolic 

• Strong association with hypertension, CKD, and cardiovascular disease
• Gout often signals elevated overall cardiometabolic risk, warranting coordinated chronic disease management 

Psychosocial 

• Stigma, embarrassment related to visible tophi, and anxiety about recurring severe pain
• Work absenteeism and quality-of-life reduction 

Nursing care that integrates pain management, mobility support, medication safety, education, and comorbidity screening can meaningfully reduce complications. 

ICD-10 code 

ICD-10-CM coding for gout distinguishes acute gout (category M10) and chronic gout (category M1A). Codes can be further specified by etiology (idiopathic, drug-induced, lead-induced, renal impairment-related, other secondary) and by anatomic site, laterality, and presence of tophi for chronic gout. 

Common high-level ICD-10-CM codes used in practice include: 

Gout (acute or unspecified pattern) 

• M10.9 Gout, unspecified
• M10.0 Idiopathic gout (with site and laterality extensions in full code set)
• M10.2 Drug-induced gout (with site and laterality extensions)
• M10.3 Gout due to impairment of renal function (with site and laterality extensions)
• M10.4 Other secondary gout (with site and laterality extensions) 

Chronic gout 

• M1A.9 Chronic gout, unspecified (full codes specify with or without tophus)
• M1A.0 Idiopathic chronic gout (full codes specify site, laterality, and with or without tophus)
• M1A.2 Drug-induced chronic gout (full codes specify site and tophus status)
• M1A.3 Chronic gout due to renal impairment (full codes specify site and tophus status) 

Tip: Coding specificity depends on provider documentation. Nursing documentation supports accuracy when it clearly describes affected joint(s), laterality, presence of tophi (visible or imaging-confirmed), functional impact, and whether gout is acute flare versus chronic disease management. 

Diagnosis 

Typical clinical presentation 

A classic acute gout flare presents with sudden onset, often overnight, of severe pain, swelling, warmth, and erythema in a single joint. The first metatarsophalangeal (MTP) joint (podagra) is a common initial site, but gout can affect many joints, including midfoot, ankles, knees, wrists, fingers, and elbows. Patients often report pain so severe that even light touch from sheets is intolerable. 

However, presentations vary: 

• Polyarticular flares may occur, especially in longstanding disease.
• Atypical locations can be seen in older adults and in those with CKD or diuretic use.
• Systemic indicators, such as low-grade fever and malaise, can occur and can resemble infection.
• Tophaceous gout may present with firm nodules on ears, fingers, olecranon bursae, or Achilles tendon, sometimes with overlying skin changes. 

Nursing assessment should also consider that cellulitis, septic arthritis, pseudogout, and trauma can mimic gout, and that coexisting infection is possible in high-risk patients. 

Gold standard confirmation 

The definitive diagnosis is identification of MSU crystals in synovial fluid or tophus aspirate: 

• Needle-shaped crystals
• Strong negative birefringence under polarized light microscopy 

Joint aspiration also allows Gram stain and culture to evaluate for septic arthritis, which is a key safety step when infection is plausible. 

When to suspect septic arthritis and escalate 

Septic arthritis is a medical emergency. Escalate for urgent evaluation and joint aspiration when any of the following are present: 

• Fever, rigors, or systemic toxicity
• Immunosuppression (for example, chronic steroids, chemotherapy, transplant)
• Prosthetic joint
• Overlying skin infection, open wound, or recent joint injection
• Marked leukocytosis or very high inflammatory markers (not specific but supportive)
• Inability to bear weight with severe pain and rapidly progressive swelling
• First-ever flare in an atypical joint, or diagnostic uncertainty 

Avoid assuming “it is just gout,” especially in older adults, those with diabetes, and those who are immunocompromised. 

Laboratory evaluation 

Serum urate 

• Serum urate can be elevated in gout but may be typical during an acute flare due to inflammatory shifts and renal handling changes. A normal urate level does not exclude gout.
• Baseline urate is helpful for long-term management, especially when planning treat-to-target ULT. 

Inflammatory markers 

• CRP and ESR can be elevated in gout and infection.
• CBC may show leukocytosis in severe flares. 

Renal and metabolic evaluation 

• Creatinine and eGFR guide medication selection and dosing, especially for colchicine, NSAIDs, and allopurinol.
• Liver enzymes may be needed for medication safety monitoring.
• Glucose or HbA1c may be relevant, especially if corticosteroids are used. 

Imaging 

Imaging is supportive and can be useful when aspiration is not feasible or when gout is chronic: 

• Ultrasound: may show the “double contour sign” (urate crystals on cartilage), tophi, and erosions.
• Dual-energy CT (DECT): can identify urate crystal deposits and help distinguish gout from other arthritides.
• Plain radiographs: may show punched-out erosions with overhanging edges in longstanding gout, but can be normal early. X-rays are also helpful to assess alternative diagnoses and structural disease. 

Classification criteria 

The 2015 ACR/EULAR gout classification criteria provide a structured approach for research and can support clinical reasoning, combining clinical pattern, serum urate level, imaging findings, and crystal confirmation.²  

In bedside practice, nurses should focus on recognizing typical patterns, prompting aspiration when needed, and supporting safe differential diagnosis and escalation. 

Differential diagnosis 

Key alternatives to consider include: 

• Septic arthritis: urgent aspiration and antibiotics after cultures per protocol.
• Calcium pyrophosphate deposition (CPPD) disease (pseudogout): often affects knees and wrists; rhomboid crystals with positive birefringence.
• Cellulitis: diffuse soft tissue infection without primary intra-articular findings.
• Trauma or hemarthrosis: especially with anticoagulation.
• Rheumatoid arthritis or psoriatic arthritis flare: may be polyarticular with chronic features.
• Osteoarthritis flare: pain and swelling, typically less intense erythema and systemic inflammation.
• Reactive arthritis: typically follows infection, may have extra-articular features. 

Nursing documentation essentials during diagnostic workup 

Clear, specific documentation supports diagnosis and safe care: 

• Onset and pattern (sudden vs gradual), location, laterality
• Pain score and functional limitations (weight-bearing ability, sleep disruption)
• Skin findings (erythema, warmth, demarcation), presence of open wounds
• Vital signs and systemic symptoms (fever, chills)
• Comorbidities and immunosuppression
• Current medications (diuretics, anticoagulants, aspirin, ULT)
• Prior gout history and typical joints involved
• Response to prior therapies
• Joint aspiration timing and results when available 

Management 

Management includes acute flare control, prevention of recurrence, urate-lowering strategies, and risk factor modification. Evidence-based guidelines emphasize a treat-to-target approach for serum urate when ULT is indicated, while using anti-inflammatory prophylaxis during initiation or titration of ULT.³ 

Acute gout flare management 

Goals 

• Rapid pain relief and reduction of inflammation
• Restoration of function and mobility
• Exclusion of infection when indicated
• Minimization of treatment adverse effects 

Nonpharmacologic measures 

• Rest the affected joint during the peak inflammatory period
• Ice packs (intermittent) to reduce pain and swelling
• Elevation when feasible
• Protect skin integrity if erythema is pronounced 

Pharmacologic options (first-line categories) 

Guidelines commonly support using one of the following as first-line therapy, tailored to patient factors: NSAIDs, colchicine, or glucocorticoids.³ 

• NSAIDs (nonsteroidal anti-inflammatory drugs)
  • Examples: naproxen, indomethacin, ibuprofen (institutional protocols vary)
  • Nursing considerations:
    • Screen for contraindications: active GI bleeding, peptic ulcer disease, advanced CKD, uncontrolled hypertension, heart failure, anticoagulation with high bleed risk, and NSAID allergy.
    • Monitor for GI symptoms, blood pressure changes, edema, and renal function changes.
    • Reinforce taking with food and avoiding duplicate NSAID products.
• Colchicine
  • Most effective when started early, ideally within 24 hours of flare onset.
  • Low-dose regimens are generally favored due to lower toxicity with comparable efficacy.
  • Nursing considerations:
    • Renal impairment increases toxicity risk; dose adjustments are often needed.
    • Major adverse effects: diarrhea, nausea, vomiting; severe toxicity can cause myopathy, bone marrow suppression, and multi-organ dysfunction.
    • Important drug interactions: strong CYP3A4 inhibitors and P-glycoprotein inhibitors (for example, certain macrolides like clarithromycin, some azole antifungals) can markedly increase colchicine levels. Escalate concerns to prescribers promptly.
    • Monitor for muscle pain or weakness, especially in patients on statins or with CKD.
• Glucocorticoids
  • Options: oral prednisone or prednisolone, intramuscular dosing, or intra-articular injection for a single joint (performed by trained clinicians).
  • Nursing considerations:
    • Useful when NSAIDs and colchicine are contraindicated.
    • Monitor blood glucose in patients with diabetes or at risk; hyperglycemia can occur even with short courses.
    • Monitor for mood changes, insomnia, fluid retention, and blood pressure elevation.
    • Reinforce taper plans when prescribed and avoid abrupt discontinuation after longer courses. 

Combination therapy 

For severe pain, polyarticular flares, or inadequate response, clinicians may use combination regimens (for example, colchicine plus NSAID, or colchicine plus steroid) while balancing toxicity risk. Nursing monitoring becomes especially important in combination therapy due to additive adverse effect potential. 

IL-1 inhibitors 

In selected refractory cases, IL-1 inhibitors may be considered by specialists. Nursing roles include infection screening, injection education, and monitoring per institutional protocols. 

Pain management and safety 

Opioids don’t treat inflammation but may be used briefly as adjuncts in severe pain when anti-inflammatory therapy is not yet effective or cannot be used. If opioids are used: 

• Monitor sedation, respiratory status, constipation, and fall risk.
• Pair with a bowel regimen as ordered and encourage mobility as tolerated. 

Management of ongoing urate-lowering therapy during flares 

A common misconception is that ULT should be stopped during a flare. In general: 

• Continue established urate-lowering therapy during acute flares, unless a clinician identifies a specific safety concern.
• Starting ULT during a flare may be appropriate in some situations under clinician guidance, but patients should be counseled that early ULT can be associated with more flares initially due to crystal mobilization.³ 

Nurses reinforce adherence and help patients understand the difference between flare medications and preventive urate-lowering medications. 

Indications for urate-lowering therapy (ULT) 

Guidelines typically recommend ULT for patients with: 

• Tophaceous gout
• Frequent flares (commonly defined as two or more per year, depending on the guidelines and clinical context)
• Radiographic damage attributable to gout
• Some high-risk scenarios such as CKD, very high serum urate, or urolithiasis, based on clinician judgment and guideline nuance³ 

Decision-making should be individualized, especially after a first flare. 

Urate-lowering therapy options 

1) Xanthine oxidase inhibitors (XOIs)

These reduce urate production and are first-line for many patients. 

Allopurinol 

• Often recommended as first-line, including in many patients with CKD when started low and titrated carefully.³
• Nursing considerations:
  • Start low and titrate to target serum urate rather than limiting dose based solely on creatinine, unless contraindicated by local protocols.
  • Monitor for rash and hypersensitivity. Allopurinol hypersensitivity syndrome is rare but serious and includes rash, fever, eosinophilia, hepatic injury, and kidney injury.
  • Be alert to high-risk populations for HLA-B*58:01-associated severe cutaneous adverse reactions. Testing is recommended in certain ancestry groups in some guidelines and clinical programs.³
  • Major interaction: azathioprine and 6-mercaptopurine require dose reduction when combined with allopurinol due to toxicity risk. Ensure prescribers are aware. 

Febuxostat 

• Alternative XOI for patients who cannot tolerate allopurinol or for whom allopurinol is ineffective at tolerated doses.
• Nursing considerations:
  • Cardiovascular safety has been debated; regulatory warnings exist in some jurisdictions based on trial data and post-marketing assessment. Clinical decisions should be individualized and aligned with current local guidance.
  • Monitor liver enzymes as ordered and reinforce adherence. 

2) Uricosurics

These increase renal urate excretion. 

Probenecid 

• More useful in patients with adequate kidney function and underexcretion physiology.
• Nursing considerations:
  • Encourage hydration to reduce kidney stone risk.
  • Not preferred in patients with nephrolithiasis history or significant CKD.
  • Review medication interactions and contraindications. 

3) Uricase therapy 

Pegloticase (intravenous) 

• Reserved for severe, refractory, tophaceous gout not controlled by standard therapy.
• Nursing considerations:
  • Infusion reactions and anaphylaxis risk require careful monitoring.
  • Pre-infusion screening and protocols vary by institution.
  • Serum urate monitoring before infusions can help detect loss of response, which increases infusion reaction risk. 

Treat-to-target approach 

A treat-to-target strategy aims to maintain serum urate below a threshold that promotes crystal dissolution: 

• Common target: < 6 mg/dL
• More stringent targets (for example, < 5 mg/dL) may be used in severe tophaceous disease or frequent flares, based on clinician judgment and guideline interpretation³ 

Nursing support includes facilitating lab monitoring, reinforcing follow-up, and explaining why medication doses may be adjusted even when symptoms have improved. 

Flare prophylaxis during ULT initiation or titration 

Anti-inflammatory prophylaxis reduces the risk of flares triggered by crystal mobilization when starting or increasing ULT. Options include: 

• Low-dose colchicine
• Low-dose NSAID with gastroprotection when appropriate
• Low-dose prednisone or prednisolone in select cases 

Guidelines often recommend prophylaxis for at least three to six months, with extension if flares continue.³ Nurses monitor tolerance, reinforce adherence, and assess for adverse effects. 

Lifestyle and comorbidity management 

Lifestyle interventions can reduce flare risk and complement medications, but are rarely sufficient alone for established gout. Nursing counseling is most effective when it is practical, nonjudgmental, and individualized. 

Helpful strategies include: 

• Hydration, especially during illness, heat exposure, and high activity
• Weight management through sustainable dietary patterns and activity plans
• Reducing or avoiding sugar-sweetened beverages and high-fructose products
• Moderating alcohol, especially beer and spirits
• Limiting organ meats and certain seafood, while maintaining adequate protein through lower-purine sources
• Encouraging low-fat dairy intake, which has been associated with lower urate levels in some studies
• Coordinating care for hypertension, diabetes, CKD, and hyperlipidemia 

Medication review is also important. Clinicians may consider alternatives to hyperuricemic agents (for example, replacing thiazide diuretics when feasible) but changes must be individualized. Nurses can identify potential contributors and communicate them to the prescribing team. 

Special populations and nursing considerations 

Chronic kidney disease 

• NSAIDs often carry higher risk.
• Colchicine requires dose adjustment and interaction vigilance.
• Allopurinol can be used with careful initiation and titration in many cases, consistent with modern guideline approaches.³ 

Older adults 

• Higher risk of polypharmacy and adverse effects
• Higher likelihood of atypical presentation and polyarticular disease
• Greater fall risk during flares due to pain and immobility 

Patients with diabetes 

• Steroids can worsen glycemic control; plan glucose monitoring and education. 

Anticoagulated patients 

• NSAIDs raise bleeding risk.
• Joint aspiration and intra-articular steroid decisions require clinician assessment of bleeding risk and local protocols. 

Hospitalized and postoperative patients 

• Flares may be triggered by stress, dehydration, and medication changes.
• Mobility plans, DVT prevention, and pain management require coordinated interdisciplinary care. 

Nursing care plan 

Nursing considerations 

• Treat new acute monoarthritis as potentially infectious until proven otherwise in high-risk scenarios. Advocate for aspiration when diagnostic uncertainty or red flags exist.
• Pain can be extreme and can rapidly impair mobility and self-care. Pair analgesia with safe mobility plans and fall prevention.
• Medication safety is central. Evaluate renal function, bleeding risk, GI risk, drug interactions, and comorbidities before administering or reinforcing therapies.
• Distinguish flare control medications (NSAIDs, colchicine, steroids) from preventive ULT (allopurinol, febuxostat, uricosurics). Reinforce that stopping ULT can increase future flares.
• Early ULT can increase flare frequency temporarily. Prophylaxis and reassurance improve adherence.
• Use stigma-sensitive education. Emphasize metabolic and genetic contributions and focus on achievable risk reduction rather than blame.
• Coordinate interprofessional care: primary care, rheumatology, pharmacy, physical therapy, nutrition services, and case management. 

Assessment 

Subjective data 

• Pain onset and pattern (sudden vs gradual), severity (0 to 10), nocturnal onset
• Affected joints, laterality, prior episodes, typical joints involved
• Functional impact: weight-bearing, ability to ambulate, self-care, sleep
• Systemic symptoms: fever, chills, malaise
• Recent triggers: alcohol intake, dietary changes, dehydration, illness, trauma, surgery
• Current and recent medications: diuretics, aspirin, anticoagulants, statins, immunosuppressants, ULT adherence
• Past medical history: CKD, hypertension, diabetes, heart failure, GI ulcer disease, kidney stones
• Allergies and prior adverse reactions to NSAIDs, colchicine, allopurinol, steroids
• Lifestyle factors: hydration, alcohol use, diet pattern, weight changes 

Objective data 

• Vital signs, especially fever and hemodynamic stability
• Joint assessment: swelling, warmth, erythema, tenderness, range of motion, effusion
• Skin assessment: cellulitis signs, wounds, tophi, ulcerations
• Mobility and fall risk evaluation
• Laboratory results: CBC, CRP/ESR as ordered, renal function, serum urate (baseline and trend), glucose if steroids used
• Imaging results if obtained
• Aspiration results when performed: crystal analysis, Gram stain, culture 

Nursing diagnosis/risk for 

Common nursing diagnoses that may apply include: 

1. Acute pain related to inflammatory joint process as evidenced by severe joint tenderness, guarding, and limited range of motion.
2. Impaired physical mobility related to pain and swelling as evidenced by inability to bear weight and decreased ambulation.
3. Self-care deficit related to acute pain and decreased mobility affecting bathing, dressing, and toileting.
4. Risk for falls related to impaired mobility, opioid use, and unfamiliar assistive devices.
5. Deficient knowledge related to gout pathophysiology, medication purpose, and adherence requirements.
6. Ineffective health management related to complex chronic regimen, comorbidities, and misconceptions about ULT.
7. Risk for bleeding related to NSAID use and or anticoagulation when applicable.
8. Risk for impaired renal function related to NSAID exposure, dehydration, or existing CKD.
9. Risk for infection related to skin breakdown over tophi, ulcers, or invasive procedures (aspiration, injections).
10. Disturbed sleep pattern related to severe nocturnal pain. 

Interventions 

1) Pain and inflammation control 

• Assess pain at regular intervals and after medication administration; document response and functional improvement.
• Administer ordered anti-inflammatory therapy promptly and safely (NSAID, colchicine, corticosteroid), verifying contraindications and dosing.
• Use adjunctive comfort measures: ice, elevation, rest, and positioning support.
• If opioids are used, implement monitoring for sedation, constipation prevention measures, and fall precautions. 

2) Mobility, function, and safety 

• Implement fall prevention strategies: call light access, assisted ambulation, nonslip socks, clear pathways, and mobility aids.
• Collaborate with PT for gait training and assistive device selection if weight-bearing is limited.
• Encourage gentle range-of-motion as inflammation improves, avoiding forced movement during severe pain.
• Plan toileting schedules and adaptive strategies to reduce unsafe transfers. 

3) Monitoring for red flags and escalation 

• Monitor for fever, hypotension, tachycardia, escalating pain out of proportion, or expanding erythema. Escalate for concern of septic arthritis or cellulitis.
• Advocate for aspiration and culture when infection is possible or diagnosis is uncertain.
• Monitor renal function and hydration status, especially if NSAIDs or colchicine are used.
• Monitor glucose in patients receiving steroids, particularly those with diabetes or stress hyperglycemia risk. 

4) Medication safety and interaction checks 

• For NSAIDs: monitor GI symptoms, blood pressure, edema, renal labs as ordered; ensure avoidance of duplicate NSAIDs.
• For colchicine: monitor GI intolerance, review interacting medications, and report muscle pain or weakness.
• For corticosteroids: monitor glucose, mood, blood pressure, and infection signs; reinforce tapering instructions when applicable.
• For allopurinol: reinforce adherence, monitor for rash, and educate on urgent reporting of systemic symptoms; ensure prescribers know about azathioprine or 6-mercaptopurine if present.
• Support pharmacist collaboration for complex cases and polypharmacy. 

5) Long-term gout control support 

• Reinforce treat-to-target concepts and the preventive purpose of ULT.
• Encourage keeping follow-up appointments for urate monitoring and dose titration.
• Promote adherence to flare prophylaxis during ULT initiation or titration.
• Assess barriers (cost, transport, side effects, misconceptions) and connect patients to resources and care coordination. 

6) Lifestyle coaching and comorbidity coordination 

• Provide individualized education on hydration, alcohol moderation, and reducing sugar-sweetened beverages.
• Support realistic dietary strategies rather than strict or punitive restrictions.
• Encourage weight management support when appropriate and desired by the patient.
• Promote management of hypertension, CKD, diabetes, and hyperlipidemia in collaboration with the care team. 

Expected outcomes 

• Patient reports pain reduction to a tolerable level within expected timeframe after anti-inflammatory therapy initiation.
• Joint swelling and erythema decrease, and functional mobility improves (for example, improved transfers and ambulation distance).
• No adverse medication events occur (stable renal function, controlled glucose when on steroids, no GI bleeding).
• If infection was a concern, appropriate diagnostic steps are completed (aspiration, cultures), and treatment is initiated promptly as indicated.
• Patient verbalizes understanding of:
  • Difference between flare treatment and urate-lowering prevention
  • Importance of continuing ULT during flares unless directed otherwise
  • Need for prophylaxis during ULT initiation and titration
• Patient demonstrates a plan for follow-up monitoring and long-term management, including serum urate checks if on ULT. 

Individual/caregiver education 

Teach-back essentials 

• “Gout is caused by urate crystals in the joint. The flare medication calms inflammation now. The urate-lowering medicine prevents crystals from building up over time.”
• “Serum urate needs to stay below the target so crystals dissolve and flares become less frequent.” 

Flare management at home 

• Start prescribed flare plan early at symptom onset, as directed.
• Rest the joint, use ice intermittently, elevate if possible.
• Avoid dehydration and excessive alcohol during flares.
• Seek urgent care for fever, severe systemic symptoms, rapidly spreading redness, or inability to move the joint. 

Urate-lowering therapy 

• Take ULT daily as prescribed even when symptom-free.
• Expect possible early increase in flares after starting ULT; prophylaxis reduces this risk.
• Keep lab appointments for urate and kidney function monitoring.
• Report rash, fever, facial swelling, or breathing difficulty urgently (possible severe drug reaction). 

Diet and lifestyle 

• Focus on high-impact changes:
  • Hydration and limiting sugar-sweetened beverages
  • Moderating alcohol (especially beer and spirits)
  • Choosing lower-purine proteins most of the time
  • Weight management through sustainable patterns
• Avoid moralizing language. Emphasize that genetics and kidney handling are major contributors. 

Caregiver guidance 

• Support mobility and safety during flares, including safe transfers and fall prevention.
• Assist with medication organization (pill boxes, reminders).
• Help with meal planning aligned with patient preferences and realistic goals.
• Encourage follow-up visits and lab monitoring adherence. 

Additional Information

Resources 

• American College of Rheumatology (patient resources and guideline information): https://rheumatology.org/
• Arthritis Foundation (patient education and lifestyle support): https://www.arthritis.org/
• CMS ICD-10-CM resources: https://www.cms.gov/medicare/coding-billing/icd-10-codes
• Food and Drug Administration (FDA). (n.d.). Febuxostat safety communication (cardiovascular risk) and prescribing information updates. https://www.fda.gov/ (search “febuxostat boxed warning” within FDA site)
• ICD-10 code lookup (ICD10Data): https://www.icd10data.com/ICD10CM/Codes
• National Kidney Foundation (CKD education relevant to gout medication safety): https://www.kidney.org/ 

References 

• Zhu Y., Pandya B.J., & Choi H.K. (October 2011). Prevalence of gout and hyperuricemia in the United States: The National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63(10):3136-3141. https://pubmed.ncbi.nlm.nih.gov/21800283/
• Neogi T., Jansen T.L.T.A., Dalbeth N., et al. (October 2015). 2015 Gout classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol. 2015. https://pubmed.ncbi.nlm.nih.gov/26352873/
• FitzGerald J.D., Dalbeth N., Mikuls T., et al. (June 2020). 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020. https://pubmed.ncbi.nlm.nih.gov/32391934/
• Richette P., Doherty M., Pascual E., et al. (January 2017). 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. https://pubmed.ncbi.nlm.nih.gov/27457514/